Skip to main content

Table 1 Characteristics of JDM patients and HC at study inclusion

From: Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study

  JDM (n= 47) HC (n= 41) p-valuec
First qHPV vaccine dose between 9 to 13 years, n (%) 20 (42.6) 9 (22.0) 0.045
First qHPV vaccine dose between 14 to 20 years, n (%) 27 (57.4) 32 (78.0) 0.045
First qHPV vaccine dose, median age in years (IQR) 16 (13.0–19.0) 14 (6.5–21.5) 0.001
Diagnosis, median age in years (IQR) 7 (0–14.5) NA NA
1 dose previous to the study, n (%) 4 (8.5) 2 (4.9) 1.000
2 doses previous to the study, n (%) 1 (2.1) 0 (0.0) 1.000
Sexual activity initiation, n (%) 9 (19.1) 11 (26.8) 0.450
Immunossupressive medications use, n (%) 35 (74.5) NA NA
JDM group Aa, n (%) [median CMAS] 12 (25.5) [52] NA NA
JDM group Ba, n (%) [median CMAS] 17 (36.2) [52] NA NA
JDM group Ca, n (%) [median CMAS] 18 (38.3) [37] NA NA
  JDM (n = 37) HC (n = 39) p-valuec
Seropositivity for HPV 16, n (%) 10 (27.0)b 2 (5.1) 0.011
Seropositivity for HPV 18, n (%) 9 (24.3)b 1 (2.6) 0.006
  1. JDM juvenile dermatomyositis, HC healthy controls, HPV human papillomavirus, qHPV quadrivalent HPV vaccine, NA not applicable, CMAS childhood myositis activity score, IQR interquartile range
  2. aJDM groups: A = inactive disease without medication; B = inactive disease with medication; C = active disease with medication. Considering active disease: CMAS < 48 or MMT < 78 or unsatisfactory physician global assessment of overall disease activity (PhyGloVAS)
  3. bSix patients were seropositive for both HPV16 and 18, four were seropositive only for HPV16, and three only for HPV18
  4. cStatistical significance was defined as a p-value < 0.05